Beta-adrenergic receptor signaling affects tumor microenvironment

September 13, 2017

(HealthDay)—β2-adrenergic receptor (β-AR) signaling in host immune cells regulates CD8+ T-cell frequency and functional orientation within the tumor microenvironment, according to a study published online Aug. 17 in Cancer Research.

Mark J. Bucsek, from Roswell Park Cancer Institute in Buffalo, N.Y., and colleagues used physiologic, pharmacologic, and genetic strategies to reduce adrenergic stress signaling in two preclinical mouse tumor models.

The researchers found that reducing β-AR signaling facilitated conversion of tumors to an immunologically active . In addition to an elevated effector CD8+ T-cell to CD4+ regulatory T-cell ratio, there was increased intra-tumoral frequency of CD8+ T-cells with an effector phenotype and decreased expression of PD-1. The conversion significantly increased the efficacy of anti-PD-1-chekpoint blockade.

"These data highlight the potential of adrenergic stress and norepinephrine-driven β-adrenergic receptor signaling to regulate the immune status of the and supports the strategic use of clinically available β-blockers in patients to improve responses to immunotherapy," the authors write.

Explore further: Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

More information: Abstract
Full Text

Related Stories

Modulating T-cell metabolism uncovers new technology for enhancing immunotherapy

September 11, 2017
T lymphocytes found in tumors and implicated in killing tumor cells cope with the shortage of oxygen and nutrients in the tumor microenvironment by using fat as the main source of energy. Promoting a switch from glucose to ...

Silencing cancer cell communication may reduce the growth of tumors

January 30, 2017
In several types of cancer, elevated expression of the chemokine receptor CCR4 in tumors is associated with poor patient outcomes. Communication through CCR4 may be one mechanism that cancer cells use to create a pro-tumor ...

Targeting blood vessels to improve cancer immunotherapy

April 12, 2017
EPFL scientists have improved the efficacy of cancer immunotherapy by blocking two proteins that regulate the growth of tumor blood vessels.

Glioblastoma 'ecosystem' redefined for more effective immunotherapy trials

July 10, 2017
A research team has revealed the intrinsic gene expression patterns of glioblastoma (GBM) tumors, insights that could drive more effective treatments for GBM, the most common and deadly malignant primary brain tumors in adults.

Gene-editing tool can improve efficacy of adoptive T-cell immunotherapy

April 15, 2016
The gene-editing tool TALEN can be used to inactivate PD-1-mediated immunosuppression and enhance the efficacy of a type of immunotherapy called adoptive T-cell transfer against solid tumors, according to a preclinical study ...

Cancer cells send signals boosting survival and drug resistance in other cancer cells

June 6, 2017
Researchers at University of California San Diego School of Medicine report that cancer cells appear to communicate to other cancer cells, activating an internal mechanism that boosts resistance to common chemotherapies and ...

Recommended for you

Targeted antibiotic use may help cure chronic myeloid leukaemia

September 19, 2017
The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research.

Bone marrow protein a 'magnet' for passing prostate cancer cells

September 19, 2017
Scientists at the University of York have shown that a protein in the bone marrow acts like a 'magnetic docking station' for prostate cancer cells, helping them grow and spread outside of the prostate.

Brain cancer breakthrough could provide better treatment

September 19, 2017
A new discovery about the most common type of childhood brain cancer could transform treatment for young patients by enabling doctors to give the most effective therapies.

Researchers compose guidelines for handling CAR T cell side effects

September 19, 2017
Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University ...

A new paradigm for treating transcription factor-driven cancers

September 18, 2017
In the current issue of Proceedings of the National Academy of Sciences, researchers from Nationwide Children's Hospital describe a new paradigm for treating transcription factor-driven cancers. The study focuses on Ewing ...

Altitude training for cancer-fighting cells

September 18, 2017
Mountain climbers and endurance athletes are not the only ones to benefit from altitude training - that is, learning to perform well under low-oxygen conditions. It turns out that cancer-fighting cells of the immune system ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.